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PTHrP and the PTH/PTHrP receptor are co-expressed in
human breast and colon tumours
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Summary Using RNA extracted from human tumour samples removed during surgery, we have analysed expression of mRNA for
parathyroid hormone-related protein (PTHrP) and for the PTH/PTHrP receptor by RT-PCR in a panel of human breast and colon tumours. All
but 1 of 18 breast tumour samples expressed PTHrP, whereas receptor expression was detected in 11 of these. Expression of the
PTH/PTHrP receptor was found in three out offour metastatic lesions, including one sample in which no receptor was detected in the primary
tumour. PTHrP expression was also detected in five colon tumours, and receptor expression detected in two of these. These results
demonstrate that PTHrP and the PTHrP receptor are also co-expressed in breast tumours in vivo and provide further evidence that PTHrP
may be an important autocrine/paracrine growth factor in breast cancer.
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Humoral hypercalcaemia of malignancy (HCM) is mediated by
tumour cell secretion of parathyroid hormone-related protein
(PTHrP), a polypeptide that shares some N-terminal homology
with the systemic calcium-regulating hormone parathyroid
hormone (PTH) (Goltzman et al, 1989; Martin and Suva, 1989).
PTH and PTHrP bind to the same cell-surface receptor (the type 1
PTH/PTHrP receptor) (Abou-Samra et al, 1992), and PTHrP
exerts many effects on target cells in common withPTH, including
elevation of intracellular cAMP (Birch et al, 1995) and [Ca2+],
(Donahue et al, 1988; Schofl et al, 1991). PTHrP has been local-
ized to a range ofnormal and fetal tissues (Moniz et al, 1990), but
its physiological role is not yet clear. It is believed, however, to be
a paracrine or autocrine regulator ofcell function.
PTHrP production has been identified in normal (Thiede and
Rodan, 1988) and malignant mammary tissue by immunocyto-
chemistry (Bundred et al, 1991; Powell et al, 1991; Bundred et al,
1992; Edwards et al, 1995 and in situ hybridization (Vargas et al,
1992), and PTHrP has been detected in the supernatants of
cultured mammary epithelial cells (Ferrari et al, 1992). In trans-
genic mice that overexpress PTHrP, there is profound breast
hyperplasia (Wysolmerski et al, 1993). These findings suggest a
role forPTHrP in the regulation ofmammogenesis. Furthermore, a
range of findings indicate that PTHrP may have a role to play in
the growth or development of growth of breast cancer. Cultured
breast cancer cells and cell lines have been shown to produce
PTHrP (Walsh et al, 1992; Francini et al, 1993), and 60% of
human breast carcinomas were found to express PTHrP immuno-
cytochemically (Southby et al, 1990).
In a previous study, we demonstrated expression of the
PTH/PTHrP receptor by a range ofhuman breast cancer cell lines,
and showed that a breast cancer cell line that expressed the
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PTH/PTHrP receptor (MCF-7), proliferated in response to exoge-
nous PTHrP (Birch et al, 1995). We therefore concluded that
expression of the PTH/PTHrP receptor by breast cancer cells in
vitro could result in PTHrP acting as an autocrine growth factor
forthese cells. The current study was undertaken to investigate the
potential relevance of this finding to breast cancer in vivo. Using
RNA extracted from primary human breast tumours removed
during surgery, we have investigated the expression ofthe PTHrP
and its receptor by primary human breast tumours and metastases.
MATERIALS AND METHODS
cDNA synthesis
Samples of total RNA (5 jg) from surgically excised breast
tumours were obtained from the Cancer Tissue Bank Research
Centre at the University of Liverpool. Ethics committee approval
had been obtained for collection and use of all of these tissue
samples. An aliquot (2.5 gg) oftotal RNA was used as a template
for first-strand cDNA synthesis in a 25 ,ul reaction volume
containing the following reagents: 0.5 mm each of dATP, dCTP,
dGTP and dTTP; 1.25 jg oligo (dT); 20 U RNAase inhibitor;
10 mM dithiothreitol; 6 mm magnesiumchloride; 40 mm potassium
chloride; 50 mm Tris-HCl (pH 8.3) and 200 Ujigg RNA Moloney
murine leukaemia virus reverse transcriptase (Gibco). The reaction
was incubated at 37°C for 1 h and terminatedby freezing at-20°C.
Polymerase chain reaction
PCR reactions were carried out using a 50 ,ul reaction volume
containing the following reagents: 0.5 gl of Taq DNA polymerase
(Gibco), 1 ,ul of sense and antisense primers (1 jig g1-1); 200 ,UM
each of dATP, dCTP, dGTP and dTTP (Pharmacia); 1.5 mm
magnesium chloride; 10 mM P-mercaptoethanol; 10mmn-Tris HCl
(pH 8.3); and 2 jl of cDNA preparation. For 0-actin, PTHrP and
PTH/PTHrP receptor PCR the following conditions of denatura-
tion, annealing and extension were employed: Stage 1, 94°C for
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Figure 1 Expression of PTHrP mRNA detected by RT-PCR. (A) PCR products from the tumour samples shown separated by electrophoresis in 1% agarose.
The specific amplification product appears at 535 bp. The last lane of the upper panels shows a 1-kb ladder. (B) Southern blots of these gels
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Figure 2 Expression of mRNA for the PTH/PTHrP receptor detected by RT-PCR. (A) PCR products from the tumour samples shown separated by
electrophoresis in 1% agarose. The specific amplification product appears at 571 bp. The last lane of the upper panels shows a 1-kb ladder. (B) Southern blots
of these gels. The breast metastases are labelled a, b, c, d in the top left panel
5 min; Stage 2, 30 cycles of94°C for 1 min, 600C (j-actin/PTHrP)
or 55°C (PTH/PTHrP receptor) for 1 min, 720C for 1 min, stage 3,
72°C for 10 min. The primers used were as follows:
1-actin
Sense
Antisense
PTHrP
Sense
Antisense
5'-GTCGGGCGCCCCAGGCACCA
5'-CTCCTTAATGTCACGCACGATlTC
5'-ATGCAGCGGAGACTGGTTCAG
5'-TCAATGCCTCCGTGAATC-
GAGCTCCAGCGACGT
PTH/PTHrP receptor
Sense 5'-AGGAACAGATCTTCCTGCTGCA
Antisense 5'-TGCATGTGGATGTAGTTGCGCGT.
Southern hybridization
PCR products were separated by agarose gel electrophoresis and
blotted onto Zetabind hybridization membrane (Cuno Products,
CT, USA) by capillary action in 0.2 M sodium hydroxide. The
membrane was rinsed in 25 mm phosphate buffer pH 6.5 and
prehybridized for 2 h at 420C in hybridization buffer (40%
formamide, 5 x SSC, 10 x Denhardt's, 200 gg ml-1 denatured
salmon sperm DNA). The membranes were then probed with a
fluorescein-labelled fragment of PTHrP (535 bp) or PTH/PTHrP
receptor (571 bp) cDNA (10 ng ml-') in the same hybridization
buffer. The fluorescein-labelled probes were prepared using an
Amersham random-prime labelling kit. Blots were probed at 42°C
for 24 h, washed 3 x 10 min in 0.2 x SSC/0.1% SDS at 60°C and
hybridized probe was detected using a peroxidase-conjugated
monoclonal mouse anti-fluorescein antibody developed using the
enhanced chemiluminescence system (ECL) from Amersham.
RESULTS
The tumour samples tested were divided into groups according to
the type of tumour. The groups were as follows:
1. Breast cancer (infiltrating ductal carcinoma), ten samples.
2. Breast cancer (invasive lobular carcinoma), four samples.
3. Breast cancer (axillary lymph node metastasis from infiltrating
ductal carcinoma), four samples. These metastatic samples were
obtained from patients in group (1) as indicated in Figure 2.
4. Colonic adenocarcinoma, five samples.
cDNA was successfully synthesized from all tumour samples as
determinedby RT-PCR for f-actin (data not shown). All but one of
the tumour samples tested, including the five colon tumours, were
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shown to express mRNA for PTHrP by RT-PCR (Figure 1).
mRNA for the PTH/PTHrP receptor was detected in five of ten
infiltrating ductal breast cancers, one of four invasive lobular
breast cancers, three of four metastatic breast cancers and two of
five colon cancers (Figure 2). Of the metastatic tumours that
expressed mRNA for the receptor, one of these was a metastasis
from a primary tumour (group 1) which did not express the
receptor. Southern hybridization confirmed the identity ofthe PCR
products and detected low-level receptor mRNA in one further
infiltrating ductal carcinoma.
DISCUSSION
We have demonstrated the expression of mRNA for PTHrP in 18
surgically excised breast tumour samples, and mRNA for the
PTH/PTHrPreceptor in 11 ofthese. The expression and/orproduc-
tion of PTHrP by a variety of tumour cells has been widely
reported, with breast tumours particularly common producers of
the protein. Although one clearly shown consequence of PTHrP
production by tumours is the well-described hypercalcaemia asso-
ciated with malignancy, the widespread detection of PTHrP in
cancers has led investigators to consider the possibility that PTHrP
might be involved in the growth or progression of the tumour. If
PTHrP does regulate tumour growth, then the susceptible tumour
cells must possess a surface receptor for the molecule. We have
recently demonstrated the expression of PTH/PTHrP receptors by
human breast cancer cell lines, and have shown that one cell line
that expresses the receptor (MCF-7) also proliferates in response
to PTHrP in vitro. Similarly, Bowcott et al (1994) and Iwamura et
al (1994) have shown mitogenic responses to PTHrP in PTHrP-
expressing prostate cancer cell lines. Tumour cell lines can there-
fore express both PTHrP and its receptor and thereby respond to
the PTHrP in an autocrine fashion.
In the current study, we have demonstrated expression of both
PTHrP and its receptor in samples of surgically removed primary
breast tumour tissue. PTHrP mRNA was detected in all breast
cancer samples studied, but receptor expression was detected in
only 11 of these tumours. In a previous study, receptor expression
was detected in three of six breast cancer cell lines; thus, only a
proportion of breast cancers possess the capacity to respond to
PTHrP. Immunohistochemisty studies have detected PTHrP in 88%
of breast tumours from patients with bone metastases compared
with 52% of tumours without metastases (Bundred et al, 1991).
This may indicate that PTHrP production by cancer cells could
predispose to the development ofbone metastases. However, in the
current study, PTHrP mRNA was also detected in all five colon
tumours, although with a lower signal strength, and to date the vast
majority of tumours we have tested have been positive for PTHrP
mRNA. Although there was also a signal for the PTH/PTHrP
receptor in a minority ofthe colon tumours, this signal was consid-
erably weaker than in the breast cancer samples. The growth of
breast cancer cells and their aggressiveness may be related both to
PTHrP expression and to their ability to respond (via the
PTH/PTHrP receptor) to the autocrine or paracrine effects of local
PTHrP production, and co-expression of PTHrP and its receptor
may be an important factor in promoting metastatic spread.
We have detected, in one instance, changes in PTHrP receptor
expression between a primary tumour and a metastasis which
could represent the selection of a metastatic cell type which was
more aggressive and responsive to the growth-promoting effects of
PTHrP. In animal models, inhibition of PTHrP production by
1, 25-dihydroxy-vitamin D3 and its analogues has prevented the
development of hypercalcaemia and inhibited growth of tumours
(Haq et al, 1993). Taken in conjunction with our data, this would
support the contention that PTHrP can act in an autocrine or
paracrine fashion to promote the growth oftumours. The data also
suggest that there could be therapeutic benefits in switching off
PTHrP production and/or antagonizing the effects ofPTHrP at the
receptor level.
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